Biomarkers of oxidative stress are associated with frailty: the Framingham Offspring Study
Biomarkers of oxidative stress are associated with frailty: the Framingham Offspring Study
复制标题
DOI：
10.1007/s11357-015-9864-z
复制
发表时间：
2016-02-01
期刊：
影响因子：
--
通讯作者：
Murabito, Joanne M.
中科院分区：
文献类型：
--
作者：
Liu, Christine K.;Lyass, Asya;Murabito, Joanne M.
心血管疾病和虚弱经常同时发生。两者都与炎症有关，炎症可能部分由氧化应激引发，特别是在心血管疾病中。我们研究了与心血管疾病相关的炎症和氧化应激生物标志物是否与虚弱和步态速度的相关结果相关。我们报告了在Frachial Offspring研究第八周期评估的生物标志物和虚弱的横截面关联。参与者年龄≥ 60岁，如果他们有关于虚弱的信息，并且至少有以下一项：C-反应蛋白，白细胞介素-6，肿瘤坏死因子受体2，8-epi-FGF α异前列腺素（异前列腺素），脂蛋白磷脂酶A2（LpPLA 2）质量或活性，骨保护素，细胞内粘附分子-1，单核细胞趋化蛋白-1或P-选择素。逐步逻辑模型用于虚弱和逐步线性模型的步态速度。协变量包括年龄、性别、体重指数、吸烟和合并症。比值比（OR）和斜率估计值（B）按对数转换生物标志物的标准差增加报告。在1919名参与者中，142人（7%）身体虚弱。在逐步模型中，虚弱几率随着白细胞介素-6（OR 1.90，95% CI 1.51，2.38）、异前列腺素（OR 1.46，95% CI 1.12，1.92）和LpPLA 2质量（OR 1.29，95% CI 1.00，1.65）的增加而增加。逐步回归发现，较慢的步态速度与白细胞介素-6有关（B=-0.025 m/s，95% CI 0.04，-0.01），异前列烷（B=-0.019，95% CI-0.03，-0.008）、LpPLA 2质量（B=-0.016，95% CI-0.03，-0.004）和骨保护素（B =-0.015，95% CI-0.03，-0.002，所有p< 0.05）。白细胞介素-6、异前列腺素和LpPLA 2质量与更大的虚弱几率和更慢的步态速度相关。氧化应激可能是导致虚弱的一种机制。
Cardiovascular disease and frailty frequently occur together. Both are associated with inflammation, which may be partially triggered by oxidative stress, especially in cardiovascular disease. We investigated whether inflammatory and oxidative stress biomarkers linked to cardiovascular disease were associated with frailty and the related outcome of gait speed. We report cross-sectional associations of biomarkers and frailty assessed at Framingham Offspring Study cycle eight. Participants >= 60 years were eligible if they had information on frailty and at least one of the following: C-reactive protein, interleukin-6, tumor necrosis factor receptor 2, 8-epi-FGF alpha isoprostanes (isoprostanes), lipoprotein phospholipase A2 (LpPLA2) mass or activity, osteoprotegerin, intracellular adhesion molecule-1, monocyte chemoattractant protein-1 or P-selectin. Stepwise logistic models were utilized for frailty and stepwise linear models for gait speed. Covariates included age, sex, body mass index, smoking, and co-morbidities. Odds ratios (ORs) and slope estimates (B) are reported per standard deviation increase of loge-transformed biomarker. Of the 1919 participants, 142 (7 %) were frail. In a stepwise model, frailty odds increased with higher interleukin-6 (OR 1.90, 95 % CI 1.51, 2.38), isoprostanes (OR 1.46, 95% CI 1.12, 1.92), and LpPLA2 mass (OR 1.29, 95 % CI 1.00, 1.65). Stepwise regression found that slower gait speeds were associated with interleukin-6 (B=-0.025 m/s, 95 % CI 0.04, -0.01), isoprostanes (B=-0.019, 95 % CI -0.03, -0.008), LpPLA2 mass (B=-0.016, 95 % CI -0.03, -0.004), and osteoprotegerin (B = -0.015, 95 % CI -0.03, -0.002, all p< 0.05). Interleukin-6, isoprostanes, and LpPLA2 mass were associated with greater frailty odds and slower gait speeds. Oxidative stress may be a mechanism contributing to frailty.